Takeda

OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Greater Chicago Food Depository

The only focused effort of its kind, Project Scientist was developed to offer girls the essential support unique to each stage of a future scientists' life serving girls/women ages 4 to PhD age. Through extensive research on current trends and practices has built a robust & focused, three-phase, program pipeline to serve as a national model for advancing girls and women, of all ages, in their STEM interests and passions.

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.

hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Their First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.

Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company focuses on discovering and developing innovative therapies for severe liver diseases. Its approach includes gene therapy, drug therapy, and cell therapy, aiming to restore liver function, halt the progression of liver disease, and address the serious complications associated with liver failure. Through its research and development efforts, Ambys Medicines seeks to significantly improve the quality of life for individuals affected by liver-related health issues.

Integra Therapeutics is a developer of next-generation of gene editing tools to cure diseases.

Developer of a behavioral health engagement platform intended to improve behavioral healthcare for underserved populations. The company's platform provides personalized care delivery services to integrate patients, providers and prescribers in the care cycle to manage the practice, enabling medical community to improve patient outcomes at minimal costs.

Cardurion Pharmaceuticals, LLC operates as a biotechnology company. The company was incorporated in 2017 and is based in Boston, Massachusetts.

Egle Therapeutics SAS, a biotechnology company, develops immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases. It develops Treg modulating drug pipeline, which includes computationally designed resurfaced IL-2 proprietary variants to engage or dis-engage Tregs. The company was founded in 2020 and is based in Paris, France.

Oshi Health is a virtual gastroenterology (GI) clinic that diagnoses, treats and remotely monitors digestive (GI) conditions. Patients work with Oshi Health's integrated care team of gastroenterologists and GI-specialized nurse practitioners, registered dietitians, behavioral psychologists and health coaches to determine the root causes of their symptoms and use a personalized care plan that includes medication, dietary interventions and stress/anxiety reduction to get symptoms under control. This yields improved health outcomes, quality of life, satisfaction with care and workplace productivity while reducing overall healthcare cost.

Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.

Transine Therapeutics

BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets.

Seqster, PDM Inc. develops a software-as-a-service (SaaS) that allows the members, payers, providers, clinical research enterprise employees, foundations, and patients to import medical data from electronic health records (EHR), genetic, and fitness data from various sources. It offers Seqster, a health data management solution to collect users' EHR, DNA, and wearables data, enabling its customers to collect, own, and share their health information on their terms. The company was founded in 2016 and is based in San Diego, California.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Adaptate is a biotherapeutics company that develops antibodies to modulate gamma delta T cells in situ. The company was founded in 2019 by Adrian Hayday and is headquartered in London.

Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.

StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.

Maverick Therapeutics is a biotech company focused on improving the lives of patients with solid tumor cancers by developing breakthrough T cell immunotherapies with improved safety and efficacy. Their highly innovative platform, COBRA™, is the most advanced bispecific T cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, founded in 2008. The company has developed an innovative platform known as the CIVO arrayed microinjection system, which allows for the simultaneous evaluation of multiple drugs or drug combinations directly within a patient's tumor. This technology assesses efficacy, resistance, and drug synergies in the tumor's native microenvironment, overcoming the limitations of traditional systemic drug administration. By employing its clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, thereby streamlining drug development. Additionally, the technology facilitates the identification of effective drug combinations and targets using RNA interference, providing a more accurate measurement of treatment efficacy tailored to individual patient responses.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

Aspen RxHealth is a service powered by an app-based platform that connects pharmacists with patients in need of enhanced medication services. Its application makes it easy for health plans and providers to connect their patients with an on-demand community of pharmacists who have time and expertise to provide clinical service.

Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.

Operator of a drug discovery platform intended to empower the rapid and efficient discovery of ribonucleic acid (RNA) targeting drugs. The company's platform integrates parallel biochemical analysis systems of species of nucleic acids, which includes various gene structures, regardless of their source organ, species, or virus, enabling patients with impactful drugs with selectivity and providing critical solutions in the RNA-targeted drug space.

Palleon Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. It offers therapeutics to treat cancer and inflammatory diseases. The company also develops drugs for inflammatory diseases, such as autoimmunity and fibrosis. Palleon Pharmaceuticals Inc. was formerly known as Palleon Pharma Inc. and changed its name to Palleon Pharmaceuticals Inc. in February 2017. The company was founded in 2015 and is based in Waltham, Massachusetts.

ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company specializes in therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein commonly found in various tumors but absent in normal tissues, making it a promising target for cancer treatment. Its lead product, VLS-101, is designed as a ROR1-directed ADC aimed at patients with both hematologic and solid tumor malignancies. Founded in 2017, VelosBio has demonstrated positive preclinical results for its ROR1-directed therapeutics, paving the way for potential use in monotherapy or in combination with other treatments across a wide range of cancers. As of late 2020, VelosBio operates as a subsidiary of Merck & Co., Inc.

Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.

Amwell is a telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 240 health systems comprised of 2,000 hospitals and 55 health plan partners with over 36,000 employers, reaching over 150 million lives. Amwell was founded in 2006 and is headquartered in Boston, Massachusetts.

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Redpin Therapeutics, Inc., gene therapy company, develops a chemo genetics platform for targeted cell therapies that address intractable diseases of the nervous system. It discovers and develops an ion channel-based chemo genetics platform that enables targeted cell activation/inhibition controlled by low doses of the anti-smoking drug Varenicline. Redpin Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion.

Seqster, PDM Inc. develops a software-as-a-service (SaaS) that allows the members, payers, providers, clinical research enterprise employees, foundations, and patients to import medical data from electronic health records (EHR), genetic, and fitness data from various sources. It offers Seqster, a health data management solution to collect users' EHR, DNA, and wearables data, enabling its customers to collect, own, and share their health information on their terms. The company was founded in 2016 and is based in San Diego, California.

EmendoBio, Inc. is a biotechnology company focused on advancing genome editing technology to repair and eliminate genetic mutations in living cells that cause serious diseases and disorders. Founded in 2015 and headquartered in New York, EmendoBio utilizes a multidisciplinary approach that combines expertise in protein engineering, DNA repair, and directed evolution. The company's mission is to develop genetic medicines that address currently untreatable disorders by innovating and enhancing existing gene editing tools. EmendoBio operates as a subsidiary of AnGes, Inc., and its team is composed of individuals with backgrounds from prestigious academic institutions, collectively working to push the boundaries of genetic medicine through creativity and scientific rigor.

EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generate first-in-class treatments for unmet needs in oncology and autoimmune diseases.

Transine Therapeutics

Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.

Oshi Health is a virtual gastroenterology (GI) clinic that diagnoses, treats and remotely monitors digestive (GI) conditions. Patients work with Oshi Health's integrated care team of gastroenterologists and GI-specialized nurse practitioners, registered dietitians, behavioral psychologists and health coaches to determine the root causes of their symptoms and use a personalized care plan that includes medication, dietary interventions and stress/anxiety reduction to get symptoms under control. This yields improved health outcomes, quality of life, satisfaction with care and workplace productivity while reducing overall healthcare cost.

Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.

ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.

Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.

Axcelead Drug Discovery Partners, Inc. specializes in drug discovery services, offering integrated drug discovery, high-throughput screening, and compound management. Founded in 2017 and headquartered in Fujisawa, Japan, the company focuses on delivering comprehensive early-stage discovery solutions. Axcelead combines scientific expertise with robust intellectual property protection and utilizes state-of-the-art facilities accredited for Good Laboratory Practice (GLP) to enhance its service offerings. The firm aims to support pharmaceutical and biotechnology companies in advancing their drug development processes efficiently and effectively.

Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company specializes in therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein commonly found in various tumors but absent in normal tissues, making it a promising target for cancer treatment. Its lead product, VLS-101, is designed as a ROR1-directed ADC aimed at patients with both hematologic and solid tumor malignancies. Founded in 2017, VelosBio has demonstrated positive preclinical results for its ROR1-directed therapeutics, paving the way for potential use in monotherapy or in combination with other treatments across a wide range of cancers. As of late 2020, VelosBio operates as a subsidiary of Merck & Co., Inc.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company focuses on discovering and developing innovative therapies for severe liver diseases. Its approach includes gene therapy, drug therapy, and cell therapy, aiming to restore liver function, halt the progression of liver disease, and address the serious complications associated with liver failure. Through its research and development efforts, Ambys Medicines seeks to significantly improve the quality of life for individuals affected by liver-related health issues.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, founded in 2016. The company focuses on discovering and developing innovative therapies for severe liver diseases. Its approach includes gene therapy, drug therapy, and cell therapy, aiming to restore liver function, halt the progression of liver disease, and address the serious complications associated with liver failure. Through its research and development efforts, Ambys Medicines seeks to significantly improve the quality of life for individuals affected by liver-related health issues.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, founded in 2008. The company has developed an innovative platform known as the CIVO arrayed microinjection system, which allows for the simultaneous evaluation of multiple drugs or drug combinations directly within a patient's tumor. This technology assesses efficacy, resistance, and drug synergies in the tumor's native microenvironment, overcoming the limitations of traditional systemic drug administration. By employing its clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, thereby streamlining drug development. Additionally, the technology facilitates the identification of effective drug combinations and targets using RNA interference, providing a more accurate measurement of treatment efficacy tailored to individual patient responses.

GEXVal Inc. engages in research and development of drugs targeting intractable/rare diseases and related operations. The company was founded in 2018 and is based in Fujisawa, Japan.

ARTham Therapeutics Inc is a biopharmaceutical company based in Naka-Ku, Japan, founded in 2018. The company focuses on developing innovative drugs and therapies aimed at treating debilitating diseases, particularly inflammatory skin conditions, vascular malformations, and endometriosis in the context of immuno-oncology. Its product pipeline includes programs such as art-648, art-ep, art-pde, and art-001, which are designed to address specific medical needs, facilitating faster recovery and improving the quality of life for patients.

Reborna Biosciences is a research and development company focused on addressing unmet medical needs in the realm of genetic rare diseases. Based in Fujisawa, Japan, the company specializes in creating therapeutic options that target ribonucleic acid using low-molecular compounds. Its innovative approach aims to develop new disease-modifying drugs for patients affected by rare genetic conditions, such as spinal muscular atrophy. Through its dedicated efforts, Reborna Biosciences seeks to contribute significantly to the treatment landscape for genetic diseases.

StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer’s disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer’s disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Founded in 1986, Shire is a corporate firm based in Ireland. The firm is a global bio-pharmaceutical company specialising in treatments for deficit and hyperactivity disorder, gastrointestinal, renal diseases and genetic disorders. In January 2019, Shire plc was acquired by Takeda Pharmaceutical Company Limited.

FIMECS is a protein degradation technology-based drug discovery biotech focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The human body is comprised of at least 18,097 proteins.It has been revealed that 1,500 of them are related to certain diseases, nevertheless only about 300 proteins have been regarded as druggable targets by small molecule drug discovery and all the rest have been undruggable.

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Wave Life Sciences Ltd. is a clinical stage genetic medicine company that specializes in the design and production of novel stereopure oligonucleotides using its proprietary PRISM platform. Focused on addressing genetic defects, the company develops therapies aimed at reducing the expression of harmful proteins or converting dysfunctional proteins into functional ones. Its primary research areas include neurologic conditions affecting the central and neuromuscular systems. Wave Life Sciences has established research and collaboration agreements with major pharmaceutical companies, including Pfizer and Takeda, to advance its oligonucleotide therapeutics. Founded in 2012, the company is headquartered in Singapore and maintains research facilities in Boston and Japan. The founding scientists, Gregory Verdine and Takeshi Wada, are recognized leaders in the field, contributing their expertise to the development of innovative nucleic acid therapeutics.

TiGenix NV (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC. is a Belgium-based biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. The Company is exploiting the power of regenerative medicine for the development of durable treatments, validated through controlled clinical studies, for these indications. TiGenix is located in Leuven and was founded as a spin-off of the Catholic University of Leuven and the University of Ghent. TiGenix is developing a portfolio of products that addresses specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction severely affecting the mobility and functioning of patients. During the fiscal year ended December 31, 2009, the Company acquired Orthomimetics Ltd.

SEEDSUPPLY research and develops medical and agricultural chemical products. The company is a spin-off of Takeda Pharmaceutical Company Limited and established in May 2017 and is headquartered in Fujisawa, Kanagawa, Japan.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Chordia Therapeutics is a clinical-stage bioventure based in Fujisawa, Japan, founded in 2017. The company specializes in the research and development of oncology drugs, focusing on creating novel therapies for cancers that have high unmet medical needs. Chordia Therapeutics is dedicated to delivering first-in-class cancer treatments to patients as swiftly as possible, addressing gaps in current therapeutic options in the oncology field.

At Outpost, they are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company's lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).

Portal Instruments, Inc., a clinical stage and medical device company, manufactures jet injectors that delivers drugs through the skin without a needle at specific depths and volumes. It develops and commercializes needle free jet injection platform for drug delivery for patients suffering from chronic disease. The company offers a precise drug concentration and viscosity agnostic technology which is compatible with pharma manufacturing processes and provides customizable disease management tools. The company was founded in 2012 and is based in Cambridge, Massachusetts.

Palleon Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. It offers therapeutics to treat cancer and inflammatory diseases. The company also develops drugs for inflammatory diseases, such as autoimmunity and fibrosis. Palleon Pharmaceuticals Inc. was formerly known as Palleon Pharma Inc. and changed its name to Palleon Pharmaceuticals Inc. in February 2017. The company was founded in 2015 and is based in Waltham, Massachusetts.

Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University. They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.

OrphoMed, Inc. develops therapies for irritable bowel syndrome with diarrhea (IBS-D), acute and chronic pain, and cystic fibrosis. Its pipeline includes ORP-101, a chemical entity designed to create a stable molecule and to confer partial μ agonist and full κ-antagonist receptor pharmacology; ORP-105, a non-addictive, centrally-acting, non-opiate analgesic; and ORP-110, a metabolically-stable, non-depletory cystic fibrosis transmembrane regulator potentiator. OrphoMed, Inc. was incorporated in 2015 and is based in San Francisco, California.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.

GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.

GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer’s disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer’s disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Scohia Pharma is a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic.

ARIAD Pharmaceuticals, based in Cambridge, Massachusetts, is a biotechnology company specializing in the discovery, development, and commercialization of oncology drugs. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor approved for the treatment of adult patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Iclusig is marketed through specialty pharmacies in the United States and is available in the European Union, Australia, Switzerland, Israel, and Canada. Additionally, ARIAD is developing Brigatinib, an investigational treatment for non-small cell lung cancer, and AP32788, targeting various solid tumors. The company also holds license agreements with Medinol Ltd. for the development and commercialization of medical devices related to ridaforolimus. Founded in 1991, ARIAD Pharmaceuticals became a subsidiary of Takeda Pharmaceuticals U.S.A., Inc. in February 2017.

PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion.

Maverick Therapeutics is a biotech company focused on improving the lives of patients with solid tumor cancers by developing breakthrough T cell immunotherapies with improved safety and efficacy. Their highly innovative platform, COBRA™, is the most advanced bispecific T cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.

Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.

EllieGrid Inc. specializes in medication management solutions, offering both hardware and software products to assist individuals and families in organizing their medications. The company has developed a Bluetooth-enabled pill box designed to help users stay on schedule with their medication routines. Complementing this, EllieGrid provides a mobile application that enables users to program the device, receive timely notifications for medication intake, and manage a comprehensive list of their medications. Additionally, the platform collects compliance data, which is accessible to caregivers and healthcare providers, facilitating timely interventions when necessary. Founded in 2015, EllieGrid is headquartered in Austin, Texas, and sells its products online.

Bioniz Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel peptide therapeutics for the treatment of immune diseases and cancer. The company’s pipeline include BNZ-1, a selective inhibitor of three interleukin cytokines (IL2/IL9/IL15) that are major disease drivers in HTLV-1 Associated Myelopathy (HAM), and in T-cell Leukemias; and IL-15 and IL-21 Inhibitors; and BNZ-3, an early stage asset targeting IL-4, IL-9, and IL-21 cytokines. Bioniz Therapeutics, Inc. was formerly known as Bioniz, LLC. The company was founded in 2009 and is based in Irvine, California.

Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.